Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 90% Improvement Relative Risk ICU admission 72% Discharge 80% Time to viral- 59% Akhtar et al. Ivermectin for COVID-19 LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 423 patients in Pakistan Lower mortality (p<0.0001) and ICU admission (p=0.00061) Akhtar et al., The Professional Medical J., doi:10.29309/TPMJ/2022.29.09.6634 Favors ivermectin Favors control
Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study
Akhtar et al., The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634
Akhtar et al., Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study, The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634
Sep 2022   Source   PDF  
  All Studies   Meta
Retrospective 423 patients in Pakistan, 216 receiving 6 day treatment, showing lower mortality, lower ICU admission, and faster viral clearance with treatment. Limited baseline information per group is provided. There were more severe patients in the ivermectin group. Logistic regression results are mentioned without full details. The difference in mortality was not statistically significant in logistic regression. This study is excluded in meta analysis: pending additional information from authors.
risk of death, 90.4% lower, RR 0.10, p < 0.001, treatment 2 of 216 (0.9%), control 20 of 207 (9.7%), NNT 11.
risk of ICU admission, 71.6% lower, RR 0.28, p < 0.001, treatment 8 of 216 (3.7%), control 27 of 207 (13.0%), NNT 11.
risk of no hospital discharge, 79.6% lower, RR 0.20, p < 0.001, treatment 10 of 216 (4.6%), control 47 of 207 (22.7%), NNT 5.5.
time to viral-, 58.8% lower, relative time 0.41, p < 0.001, treatment mean 8.39 (±2.04) n=216, control mean 20.38 (±6.32) n=207.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Akhtar et al., 1 Sep 2022, retrospective, Pakistan, peer-reviewed, mean age 51.9, 9 authors, dosage 12mg days 1-6.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: COVID-19 Mortality and Ivermectin The Professional Medical Journal 2022, Volume, 29 Issue, 09 ORIGINAL ARTICLE Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study. Tehseen Akhtar1, Amber Hanif2, Pyar Ali3, Muhammad Hussain Haroon4, Nimra Akram5, Muhammad Umar Raza6, Khalid Imran7, Nimra Shakeel8, Ramsha Shakeel9 Article Citation: Akhtar T, Hanif A, Ali P, Haroon MH, Akram N, Raza MU, Shakeel N, Shakeel R. Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study. Professional Med J 2022; 29(9):1384-1391. ABSTRACT… Objective: To investigate the efficacy of ivermectin in the treatment of mild, moderate, and severe COVID-19 infection. Study Design: Retrospective Cohort study. Setting: COVID-19 Treatment Centre, Dr. Ruth K M Pfau Civil Hospital Karachi. Period: July 2020 to December 2020. Material & Methods: Medical records of 423 patients during a selected duration of 6 months were reviewed. Patients were stratified into two groups based on whether or not they received a 6-day course of ivermectin in addition to the standard treatment for COVID-19. Primary outcome measures were rate of mortality, days from the start of treatment to negative SARS-CoV-2 PCR, and rate of step-up to the intensive care unit. Results: Patients who received ivermectin required a lesser number of days (8.39 days ± 2.04) to become COVID negative than the patients who didn’t receive ivermectin (20.38 days ± 6.32), (p < 0.001). Multinomial logistic regression showed that the patients who were given ivermectin for COVID 19 infection were four times more likely to be discharged home than stepping up to ICU. The ICU step-up rate in the ivermectin group was found to be 3.7% compared to 13.04% in the non-ivermectin group. No significant differences in mortality were found. Conclusion: Treatment with ivermectin in COVID-19 infection is associated with improved outcomes in terms of reduction in duration of illness as well as the progression of disease severity. Key words: Ivermectin, COVID-19, SARS-CoV-2, Mortality.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop